MDX Meldex

    RNS Number : 1912B
  Meldex International PLC
  13 August 2008
   

 For Immediate Release  13 August 2008


    Meldex International plc
    ("Meldex International" or the "Company")

    Application for listing

    London, UK, 13 August 2008, Meldex International (AIM: MDX) the specialty pharma and healthcare company, announces that application has
been made to AIM, a market of the London Stock Exchange plc, for the admission of 10,936,648 ordinary shares of 1p each (the "New Ordinary
Shares") and which are being issued at a price of 54.75p per share. 

    The New Ordinary Shares have been allotted, as vendor consideration to Melmed Holding AG to satisfy the Company's earn out obligations
pursuant to the Sale and Purchase Agreement for the Melbrosin acquisition dated 27 June 2007. 

    The New Ordinary Shares will be the subject of a lock in agreement for a period of 12 months and will rank pari passu with the existing
ordinary shares of the Company.

    Trading in the New Ordinary Shares is expected to commence on AIM on Monday 18 August 2008.

    For further information:

 Meldex International Plc        + 44 (0) 20 7098 9880

 Buchanan Communications         + 44 (0) 20 7466 5000

 Nomura Code Securities Limited  + 44 (0) 20 7776 1200



    About Meldex International Plc
    Meldex International plc is an innovative specialty pharmaceutical and OTC product. Listed on London's AIM in May 2003, the Company has
over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with
several global healthcare companies. Meldex has acquired sales and marketing resources within Europe and the US as a launch mechanism for
its own pharmaceutical products. Meldex acquired the Melbrosin business in June 2007 for a consideration of up to EUR35m. Melbrosin's focus
is on consumer over the counter health care products based on substances of natural and plant origin which are developed into consumer
orientated brands then scaled, produced and distributed by Melbrosin. The Melbrosin complements the prescription pharmaceutical sales and
marketing business created and expanded in 2006.

    The business continues to develop innovative delivery mechanisms enhancing both its own product range and those of selected partners
using its proprietary XGELTM polymer technology. For further information please go to www.meldexinternational.com




This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
LISGUUGURUPRGQP

Meldex (LSE:MDX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Meldex (LSE:MDX)
Historical Stock Chart
From Jul 2023 to Jul 2024